DB:PTU

Stock Analysis Report

Executive Summary

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Prescient Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PTU's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-22.2%

PTU

-11.1%

DE Biotechs

-9.1%

DE Market


1 Year Return

-43.2%

PTU

-2.9%

DE Biotechs

2.9%

DE Market

Return vs Industry: PTU underperformed the German Biotechs industry which returned 2.8% over the past year.

Return vs Market: PTU underperformed the German Market which returned 6.5% over the past year.


Shareholder returns

PTUIndustryMarket
7 Day-22.2%-11.1%-9.1%
30 Day-28.8%-12.8%-7.2%
90 Day-56.3%-9.6%-6.5%
1 Year-42.2%-43.2%-2.7%-2.9%6.1%2.9%
3 Year-63.1%-63.8%25.8%24.4%3.5%-5.6%
5 Year-68.2%-69.6%1.6%-0.5%8.0%-6.8%

Price Volatility Vs. Market

How volatile is Prescient Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Prescient Therapeutics undervalued compared to its fair value and its price relative to the market?

1.18x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PTU's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PTU's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PTU is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PTU is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTU is good value based on its PB Ratio (1.3x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Prescient Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

34.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTU's revenue (71.9% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: PTU's revenue (71.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTU's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Prescient Therapeutics performed over the past 5 years?

-15.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTU is currently unprofitable.

Growing Profit Margin: PTU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTU is unprofitable, and losses have increased over the past 5 years at a rate of -15.1% per year.

Accelerating Growth: Unable to compare PTU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: PTU has a negative Return on Equity (-26.52%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Prescient Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PTU's short term assets (A$11.6M) exceed its short term liabilities (A$668.0K).

Long Term Liabilities: PTU's short term assets (A$11.6M) exceed its long term liabilities (A$17.8K).


Debt to Equity History and Analysis

Debt Level: PTU is debt free.

Reducing Debt: PTU had no debt 5 years ago.


Balance Sheet

Inventory Level: PTU has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PTU's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTU has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PTU has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -20.4% each year.


Next Steps

Dividend

What is Prescient Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.9%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate PTU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PTU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTU's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Yatomi-Clarke Lee 0

4yrs

Tenure

AU$585,573

Compensation

Mr. Yatomi-Clarke Steven Lee has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Lee has been Director of Prescient Therapeutics Limited si ...


CEO Compensation Analysis

Compensation vs Market: Yatomi-Clarke's total compensation ($USD385.25K) is about average for companies of similar size in the German market ($USD415.71K).

Compensation vs Earnings: Yatomi-Clarke's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Yatomi-Clarke Lee
MD, CEO & Director 4yrsAU$585.57k1.16% A$116.6k
Said Sebti
Chief Scientific Officer4.8yrsAU$168.70k0.22% A$21.9k
Terrence Chew
Chief Medical Officer4.8yrsAU$165.30kno data
Melanie Jaye Leydin
Company Secretary5yrsAU$102.00k0.063% A$6.3k
Claudia Gregorio-King
Vice President of Operations0yrsno datano data
James Winkler
Head of Business Development1.3yrsno datano data

4.8yrs

Average Tenure

64yo

Average Age

Experienced Management: PTU's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yatomi-Clarke Lee
MD, CEO & Director 4yrsAU$585.57k1.16% A$116.6k
Steven Engle
Non-Executive Chairman5.3yrsAU$82.75kno data
James Campbell
Non-Executive Director5.3yrsAU$54.09k0.054% A$5.4k
Rodney Sinclair
Chairman of Clinical Advisory Board8.7yrsno datano data
Reinhard Dummer
Member of Clinical Advisory Board8.7yrsno datano data
Joshua Douglas
Member of Scientific Advisory Board5.4yrsno datano data
Farhad Ravandi
Member of Scientific Advisory Board4.3yrsno datano data
Jeffrey Lancet
Member of Scientific Advisory Board4.3yrsno datano data
Thomas Prebet
Member of Scientific Advisory Board4.1yrsno datano data

5.3yrs

Average Tenure

Experienced Board: PTU's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.7%.


Top Shareholders

Company Information

Prescient Therapeutics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Prescient Therapeutics Limited
  • Ticker: PTU
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$16.953m
  • Listing Market Cap: AU$10.014m
  • Shares outstanding: 394.26m
  • Website: https://ptxtherapeutics.com

Location

  • Prescient Therapeutics Limited
  • 100 Albert Road
  • Level 4
  • South Melbourne
  • Victoria
  • 3205
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RANCHIA (Chi-X Australia)NPVAUAUDNo data
PTXASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 1992
PTUDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
PTXCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 1992
PSTT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992

Biography

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company’s lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. It has a collaboration agreement with Carina Biotech to develop next generation cellular therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/28 21:01
End of Day Share Price2020/02/28 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.